A systems approach to combat the significant antibiotic resistance challenge: Novel therapeutic strategies, mechanistic discoveries, and drug development

耐抗生素的“超级细菌”是一个重大的全球医学挑战。多粘菌素是唯一有效的抗生素对革兰氏阴性菌，虽然有限的药理学数据可用于其最佳使用。在接下来的5年里，我将重新开发多粘菌素，并发现针对高优先级病原体的新型抗生素。我的研究目标是世界卫生组织和美国传染病协会强调的“坏虫子，没有药物”未满足的医疗需求。

Antibiotic-resistant ‘superbugs’ are a significant global medical challenge. Polymyxins are the only effective antibiotics against Gram-negative bacteria, although limited pharmacological data are available for their optimal use. In the next 5 years, I will re-develop polymyxins and discover novel antibiotics against high-priority pathogens. My research targets the “Bad Bugs, No Drugs” unmet medical need highlighted by the World Health Organization and The Infectious Diseases Society of America.